Quest PharmaTech Inc (QPT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quest PharmaTech Inc (QPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3344
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quest PharmaTech Inc (Quest), formerly Altachem Pharma Ltd is a pharmaceutical company that develops antibody based immunotherapeutic products for the treatment of cancer. The company develops products for treatment of cancer by combining immunotherapeutic antibodies with immunoglobulin G or E, chemotherapy, immune-adjuvants, or photodynamic therapy. It owns and utilizes photodynamic therapy technology for oncology and dermatology applications. It offers products such as anti CA125 MAb oregovomab, anti MUC1 MAb AR20.5 and SL052. Quest’s anti CA125 MAb Oregovomab is an immunotherapeutic product for the treatment of ovarian cancer. The company’s SL052 is an injectable formulation that is in phase I clinical trials used for the treatment of prostate cancer. Quest is headquartered in Edmonton, Alberta, Canada.

Quest PharmaTech Inc (QPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 11
Quest PharmaTech To Acquire AllergoOncology Technology Of Advanced Immune Therapeutics 12
Venture Financing 13
OncoQuest Raises USD13 Million in Venture Financing 13
Partnerships 14
OncoQuest Enters into Agreement with Tesaro 14
OncoQuest and Shenzhen Hepalink Pharma Form Joint Venture 15
Quest PharmaTech Enters Into Co-Development Agreement With AD Biotech 16
Licensing Agreements 17
Quest PharmaTech Enters into Licensing Agreement with Bioceltran 17
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 18
Quest PharmaTech Enters Into Licensing Agreement With Oncovir For Hiltonol 19
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 20
Equity Offering 21
OncoQuest Raises USD6 Million in Private Placement of Shares 21
Quest Pharma Raises USD1.34 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoQuest Raises USD13 Million in Private Placement of Preference Shares 23
Quest PharmaTech Raises USD1.5 Million in Private Placement of Shares 24
Quest PharmaTech Raises USD0.8 Million in Private Placement of Units 25
Quest PharmaTech Completes Private Placement Of Units For US$1 Million 26
Quest PharmaTech Announces Private Placement Of Shares For US$7.7 Million 27
Quest PharmaTech Completes Private Placement Of Shares For US$0.5 Million 28
Asset Transactions 29
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 29
Acquisition 30
Quest PharmaTech to Acquire 32% Stake in Natural Rf Life Sciences for USD0.4 Million 30
Quest PharmaTech Inc – Key Competitors 31
Quest PharmaTech Inc – Key Employees 32
Quest PharmaTech Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Jul 19, 2017: Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 11
Quest PharmaTech To Acquire AllergoOncology Technology Of Advanced Immune Therapeutics 12
OncoQuest Raises USD13 Million in Venture Financing 13
OncoQuest Enters into Agreement with Tesaro 14
OncoQuest and Shenzhen Hepalink Pharma Form Joint Venture 15
Quest PharmaTech Enters Into Co-Development Agreement With AD Biotech 16
Quest PharmaTech Enters into Licensing Agreement with Bioceltran 17
Quest PharmaTech Enters Into Licensing Agreement With University Of California At Los Angeles For Cancer Treatment 18
Quest PharmaTech Enters Into Licensing Agreement With Oncovir For Hiltonol 19
Quest PharmaTech Enters Into Licensing Agreement With Stanford University For Anti-MUC1 IgE Technology 20
OncoQuest Raises USD6 Million in Private Placement of Shares 21
Quest Pharma Raises USD1.34 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoQuest Raises USD13 Million in Private Placement of Preference Shares 23
Quest PharmaTech Raises USD1.5 Million in Private Placement of Shares 24
Quest PharmaTech Raises USD0.8 Million in Private Placement of Units 25
Quest PharmaTech Completes Private Placement Of Units For US$1 Million 26
Quest PharmaTech Announces Private Placement Of Shares For US$7.7 Million 27
Quest PharmaTech Completes Private Placement Of Shares For US$0.5 Million 28
OncoQuest Acquires Immuno-Photodynamic Therapy Assets from Quest Pharma for USD2 Million 29
Quest PharmaTech to Acquire 32% Stake in Natural Rf Life Sciences for USD0.4 Million 30
Quest PharmaTech Inc, Key Competitors 31
Quest PharmaTech Inc, Key Employees 32
Quest PharmaTech Inc, Subsidiaries 33

List of Figures
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quest PharmaTech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quest PharmaTech Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Quest PharmaTech Inc (QPT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nissan Motor Co., Ltd.:企業の戦略・SWOT・財務分析
    Nissan Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nissan Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • Xeikon N.V.:企業の戦略的SWOT分析
    Xeikon N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Vaxil Bio Ltd (VXL):製薬・医療:M&Aディール及び事業提携情報
    Summary Vaxil Bio Ltd (Vaxil Bio), formerly Emerge Resources Corp, is a drug development company that develops immunotherapy platform. The company’s immunptherapy pipeline products include antigen specific immunotherapies, signal peptide specific antibodies and anti-infectives. It develops Vaxhit te …
  • Baoviet Holdings
    Baoviet Holdings - Strategy, SWOT and Corporate Finance Report Summary Baoviet Holdings - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Basler Kantonalbank AG:企業の戦略・SWOT・財務情報
    Basler Kantonalbank AG - Strategy, SWOT and Corporate Finance Report Summary Basler Kantonalbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Colorlab Custom Cosmetics, Inc:企業の戦略・SWOT・財務情報
    Colorlab Custom Cosmetics, Inc - Strategy, SWOT and Corporate Finance Report Summary Colorlab Custom Cosmetics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Chembio Diagnostic Inc (CEMI):企業の財務・戦略的SWOT分析
    Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Artios Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Artios Pharma Ltd (Artios Pharma) is an independent company that focuses on the development of DNA Damage Response (DDR) therapies to treat cancer. The company has in-licensed its lead DDR programme, DNA polymerase theta (PolO) from Cancer Research Technology (CRT), which target proteins tha …
  • 3M India Limited (3MINDIA):企業の財務・戦略的SWOT分析
    3M India Limited (3MINDIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Tenet Healthcare Corporation:企業の戦略・SWOT・財務情報
    Tenet Healthcare Corporation - Strategy, SWOT and Corporate Finance Report Summary Tenet Healthcare Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Miltenyi Biotec GmbH-医療機器分野:企業M&A・提携分析
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company which provides biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company's services include sample preparation, cell separation, flow cytometry, cell cultur …
  • Ashok Leyland Limited:企業の戦略・SWOT・財務分析
    Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report Summary Ashok Leyland Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hollingsworth & Vose Company:企業の戦略的SWOT分析
    Hollingsworth & Vose Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • MedDay SA:製薬・医療:M&Aディール及び事業提携情報
    Summary MedDay SA (MedDay) is a biotechnology company that develops drugs for nervous system disorders. The company provides clinical and pharmaceutical development in the field of rare inborn errors of metabolism to treat elucidation of metabolism pathways in the brain. Its pipeline products compri …
  • UGI Corp (UGI):企業の財務・戦略的SWOT分析
    UGI Corp (UGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Carmot Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carmot Therapeutics Inc (Carmot Therapeutics) is a biotechnology company that discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. The company provides product portfolio such as encompasses investigational candidates in preclinical trials: peptide-sm …
  • Arden Partners Plc (ARDN):企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Arden distribution services include providing unique trading thou …
  • Aavin Equity Advisors, LLC:企業の戦略・SWOT・財務分析
    Aavin Equity Advisors, LLC - Strategy, SWOT and Corporate Finance Report Summary Aavin Equity Advisors, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • International Consolidated Airlines Group, S.A.:戦略・SWOT・企業財務分析
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆